Related references
Note: Only part of the references are listed.Should inflammatory pathways be targeted for the prevention and treatment of hypertension?
Setor K. Kunutsor et al.
HEART (2019)
Inflammation markers and risk of developing hypertension: a meta-analysis of cohort studies
Ahmad Jayedi et al.
HEART (2019)
Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure
Brendan M. Everett et al.
CIRCULATION (2019)
Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)
Paul M. Ridker et al.
EUROPEAN HEART JOURNAL (2018)
Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial
Paul M. Ridker et al.
LANCET (2018)
Dietary Docosahexaenoic Acid Reduces Oscillatory Wall Shear Stress, Atherosclerosis, and Hypertension, Most Likely Mediated via an IL-1-Mediated Mechanism
Mabruka A. Alfaidi et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2018)
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
Paul M. Ridker et al.
LANCET (2017)
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
P. M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Anakinra reduces blood pressure and renal fibrosis in one kidney/DOCA/salt-induced hypertension
Yeong Hann Ling et al.
PHARMACOLOGICAL RESEARCH (2017)
Interleukin-1 Receptor Activation Potentiates Salt Reabsorption in Angiotensin II-Induced Hypertension via the NKCC2 Co-transporter in the Nephron
Jiandong Zhang et al.
CELL METABOLISM (2016)
The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study
Allison C. Morton et al.
EUROPEAN HEART JOURNAL (2015)
Interferon-γ Signaling Inhibition Ameliorates Angiotensin II-Induced Cardiac Damage
Lajos Marko et al.
HYPERTENSION (2012)
Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: Rationale and Design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)
Paul M. Ridker et al.
AMERICAN HEART JOURNAL (2011)
Monoclonal antibodies targeting IL-1 beta reduce biomarkers of atherosclerosis in vitro and inhibit atherosclerotic plaque formation in Apolipoprotein E-deficient mice
Vinay Bhaskar et al.
ATHEROSCLEROSIS (2011)
Inflammation, Immunity, and Hypertension
David G. Harrison et al.
HYPERTENSION (2011)
Central and Peripheral Mechanisms of T-Lymphocyte Activation and Vascular Inflammation Produced by Angiotensin II-Induced Hypertension
Paul J. Marvar et al.
CIRCULATION RESEARCH (2010)
Interleukin 17 Promotes Angiotensin II-Induced Hypertension and Vascular Dysfunction
Meena S. Madhur et al.
HYPERTENSION (2010)
A Role for Angiotensin II Type 1 Receptors on Bone Marrow-Derived Cells in the Pathogenesis of Angiotensin II-Dependent Hypertension
Steven D. Crowley et al.
HYPERTENSION (2010)
Interleukin-1 Regulates Multiple Atherogenic Mechanisms in Response to Fat Feeding
Janet Chamberlain et al.
PLOS ONE (2009)
C-reactive protein causes downregulation of vascular angiotensin subtype 2 receptors and systolic hypertension in mice
Wanpen Vongpatanasin et al.
CIRCULATION (2007)
Blood pressure, C-reactive protein, and risk of future cardiovascular events
GJ Blake et al.
CIRCULATION (2003)
C-reactive protein and the risk of developing hypertension
HD Sesso et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Immunosuppressive treatment protects against angiotensin II-induced renal damage
DN Muller et al.
AMERICAN JOURNAL OF PATHOLOGY (2002)
Share Paper
